Latest news

• Biogen’s Vumerity recommended by CHMP in MS

  A thumbs up for Vumerity in the EU could ease the way for Biogen’s follow-up to Tecfidera in multiple sclerosis. ... Vumerity has since overtaken Tecfidera to become the number one prescribed oral MS therapy in the country.

• Biogen pays InnoCare $125m upfront for potential multiple sclerosis treatment

  Orelabrutinib will fit neatly into Biogen’s MS portfolio, which includes Tecfidera (dimethyl fumarate), Tysabri (natalizumab) and Vumerity (diroximel fumarate).

• Biogen reveals new data for MS therapies Tysabri and Vumerity

  Biogen has announced new data for its multiple sclerosis therapies Tysabri and Vumerity, including analyses of extended interval dosing (EID) and new real-world experience data. ... In addition to the Tysabri data, Biogen also disclosed findings on the

• Biogen triumphs over Mylan’s Tecfidera patent challenge

  Biogen does, however, have its own next-generation MS treatment – Vumerity (diroximel fumarate) – which was recently approved for the treatment of relapsing forms of the disease. ... For comparison, while Tecfidera is a billion-dollar product,

• Biogen under fire over $88,000 Vumerity annual price

  Vumerity is Biogen’s answer to the patent pressures on Tecfidera, but there have been concerns that. ... Consensus estimates compiled by EvaluatePharma reflect this with forecast sales of Vumerity at a modest $111m in 2024.